Your browser doesn't support javascript.
Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
Hashimoto, Masayuki; Aoe, Shinpei; Kawazu, Yusuke; Seki, Naomi M; Hashimoto, Kumi; Yoshihara, Ken; Homma, Tomoyuki; Sonoyama, Takuhiro; Omoto, Shinya.
  • Hashimoto M; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: masayuki.hashimoto@shionogi.co.jp.
  • Aoe S; Shionogi TechnoAdvance Research Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: shinpei.aoe@shionogi.co.jp.
  • Kawazu Y; Shionogi TechnoAdvance Research Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: yusuke.kawazu@shionogi.co.jp.
  • Seki NM; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: naomi.seki@shionogi.co.jp.
  • Hashimoto K; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: kumi.hashimoto@shionogi.co.jp.
  • Yoshihara K; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: ken.yoshihara@shionogi.co.jp.
  • Homma T; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: tomoyuki.homma@shionogi.co.jp.
  • Sonoyama T; Shionogi & Co., Ltd., Drug Development and Regulatory Science Division, 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan. Electronic address: takuhiro.sonoyama@shionogi.co.jp.
  • Omoto S; Shionogi & Co., Ltd., Biopharmaceutical Research Division, 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address: shinya.oomoto@shionogi.co.jp.
Vaccine ; 40(52): 7520-7525, 2022 Dec 12.
Article in English | MEDLINE | ID: covidwho-2106128
ABSTRACT
SARS-CoV-2 Omicron subvariants such as BA.2.12.1, BA.4 and BA.5 have been spreading rapidly and become dominant worldwide. Here we report the homologous or heterologous booster effects of S-268019-b, a recombinant spike protein vaccine with the squalene-based adjuvant A-910823 in cynomolgus macaques. In macaques which had been primed with S-268019-b or mRNA vaccines, boosting with S-268019-b enhanced neutralizing antibodies (NAb) against ancestral SARS-CoV-2. Since boosting with the antigen without adjuvant did not efficiently restore NAb titers, adjuvant A-910823 was essential for the booster effect. Importantly, boosting with S-268019-b enhanced NAb against all of the Omicron subvariants we tested, including BA.2.12.1, BA.4 and BA.5, in comparison to two vaccine doses. Additionally, expansion of Omicron-specific B cells was confirmed after boosting with S-268019-b. These results indicate that a booster dose of S-268019-b with the adjuvant enhances the neutralization breadth.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Squalene / COVID-19 Topics: Vaccines / Variants Limits: Animals Language: English Journal: Vaccine Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Squalene / COVID-19 Topics: Vaccines / Variants Limits: Animals Language: English Journal: Vaccine Year: 2022 Document Type: Article